Product information and disease descriptionPlace of product in therapyApproaches to treatment
Place in treatment, anticipated use, and care setting
1 evidence topic · 5 sources
Summary
The proposed U.S. indication positions saroglitazar as combination treatment with UDCA in adults with an inadequate response, or as monotherapy in patients unable to tolerate UDCA. This is a proposed indication, not an approved prescribing recommendation. PBC management consensus includes referral to a centre with specific clinical and research expertise in PBC. The expanded-access policy requires requests from the treating physician and does not guarantee access.